Tech medical breakthrough

23andMe Identifies GLP-1 Genetic Predictors

Analysis based on 14 articles · First reported Apr 08, 2026 · Last updated Apr 17, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

This medical breakthrough by 23andMe is expected to significantly impact the pharmaceutical and healthcare markets by enabling more personalized approaches to obesity treatment. It could lead to improved patient outcomes for GLP-1 medications like Semaglutide and Tirzepatide, potentially increasing their adoption and reducing trial-and-error prescribing.

Biotechnology Pharmaceuticals Healthcare

Event Summary

23andMe Research Institute announced the publication of a study in Nature (journal) that identifies genetic predictors for the efficacy and side effects of GLP-1 receptor agonists, including Semaglutide and Tirzepatide. The large-scale genome-wide association study, involving 27,885 individuals, found that variations in GLP1R and GIPR genes are associated with differences in weight loss and the incidence of nausea and vomiting. Specifically, a missense variant in GLP1R is linked to increased weight loss efficacy, while variations in both GLP1R and GIPR are associated with nausea and vomiting, with the GIPR association being specific to Tirzepatide. These findings lay the groundwork for personalized obesity treatment strategies, where genetic testing could guide medication selection. 23andMe has also launched a new 'GLP-1 Medications Weight Loss and Nausea' report for its Total Health service members, offering personalized insights under clinician guidance. Adam Auton and Noura Abul-Husn from 23andMe highlighted the significance of these discoveries for advancing precision medicine.

Key Actions

100 23andMe published a study identifying genetic predictors for GLP-1 efficacy and side effects Nature (journal)

90 23andMe released a new report 'GLP-1 Medications Weight Loss and Nausea'

Entities Involved

stock

23andMe

23andMe Research Institute, a nonprofit medical research organization, announced the publication of a study that identifies genetic predictors for GLP-1 weight loss efficacy and side effects. This research, published in Nature, leverages data from 27,885 individuals and provides direct evidence that genetic variations influence responses to GLP-1 medications. The company has also released a new report, 'GLP-1 Medications Weight Loss and Nausea', to members of its Total Health service, offering personalized insights based on these findings.

Importance 100 Sentiment 75

per

Adam Auton

Adam Auton, Vice President of Human Genetics at 23andMe Research Institute and an author of the study, highlighted the power of their crowdsourced research community in advancing scientific understanding of human genetic variation.

Importance 50 Sentiment 60

per

Noura Abul-Husn

Dr. Noura Abul-Husn, Chief Medical Officer at the 23andMe Research Institute, emphasized that the new GLP-1 report is part of their Total Health service, where clinician guidance is crucial for contextualizing genetic results within a patient's full health picture.

Importance 50 Sentiment 60

priv

Nature (journal)

Nature (journal) is the scientific journal where the study identifying genetic predictors for GLP-1 weight loss efficacy and side effects was published, lending credibility and broad dissemination to the findings.

Importance 30 Sentiment 50

Relationships

Adam Auton related ↔ 23andMe

Noura Abul-Husn related ↔ 23andMe

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard